BidaskClub upgraded shares of Intrexon (NASDAQ:XON) from a sell rating to a hold rating in a research report sent to investors on Thursday morning, BidAskClub reports.

XON has been the topic of a number of other research reports. Northland Securities lowered shares of Intrexon from an outperform rating to a market perform rating in a research note on Friday, March 1st. JMP Securities reaffirmed a buy rating and set a $43.00 target price on shares of Intrexon in a research note on Wednesday, March 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $28.60.

Shares of XON opened at $4.84 on Thursday. The stock has a market cap of $773.28 million, a PE ratio of -3.53 and a beta of 2.18. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.57 and a current ratio of 3.91. Intrexon has a 1-year low of $3.95 and a 1-year high of $19.94.

Intrexon (NASDAQ:XON) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). The firm had revenue of $23.30 million for the quarter, compared to analyst estimates of $32.12 million. Intrexon had a negative net margin of 363.14% and a negative return on equity of 26.52%. The company’s revenue for the quarter was down 41.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.36) EPS. Research analysts expect that Intrexon will post -1.17 EPS for the current year.

In other Intrexon news, CEO Randal J. Kirk purchased 1,257,727 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was bought at an average cost of $4.40 per share, with a total value of $5,533,998.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Randal J. Kirk sold 41,678 shares of Intrexon stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $0.67, for a total transaction of $27,924.26. The disclosure for this sale can be found here. Insiders have bought a total of 2,715,593 shares of company stock worth $12,208,403 in the last ninety days. Insiders own 48.20% of the company’s stock.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: Rule of 72

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.